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Natural genetic variation affects the composition of phytochemicals 
in plants and can be of great economic importance. With a record 
of use by humans as food, fiber, and medicine spanning thousands 
of years (Faeti et al., 1996), recent decades of prohibition, and a rap-
idly changing regulatory context, Cannabis sativa L. (Cannabaceae) 
was until recently among the least studied agricultural crops (Small, 
2016). Prominent among the traits of C. sativa are cannabinoids, a 
unique class of specialized metabolites synthesized and stored in 
glandular trichomes that are located on the floral bracts of pistil-
late inflorescences (Livingston et al., 2020; Fig. 1A–C). The ratio 
of the two most abundant cannabinoids, tetrahydrocannabinolic 
acid (THCA) and cannabidiolic acid (CBDA), hereafter THC and 
CBD, is represented by three main classes: THC-type plants with 
THC:CBD ≥ 10, intermediate-type plants with THC:CBD ≈ 1, and 
CBD-type plants with THC:CBD ≤ 0.1 (de Meijer et al., 2003). Some 
authors have referred to these chemotype (chemical phenotype) 
classes as Type I, Type II, and Type III (Small, 2016). Here we in-
troduce for clarity a more descriptive classification of THC-type, 
intermediate-type, and CBD-type plants. Descriptive terms also 
avoid confusion associated with recent statutory definitions of C. 
sativa that vary widely among political jurisdictions (e.g., “indus-
trial hemp” and “medical marijuana”). Our findings suggest that 
patterns of cannabinoid inheritance render some of these popular 
definitions inaccurate at least from a botanical perspective.
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PREMISE: How genetic variation within a species affects phytochemical composition is 
a fundamental question in botany. The ratio of two specialized metabolites in Cannabis 
sativa, tetrahydrocannabinol (THC) and cannabidiol (CBD), can be grouped into 
three main classes (THC-type, CBD-type, and intermediate type). We tested a genetic 
model associating these three groups with functional and nonfunctional alleles of the 
cannabidiolic acid synthase gene (CBDAS).
METHODS: We characterized cannabinoid content and assayed CBDAS genotypes of >300 
feral C. sativa plants in Minnesota, United States. We performed a test cross to assess CBDAS 
inheritance. Twenty clinical cultivars obtained blindly from the National Institute on Drug 
Abuse and 12 Canadian-certified grain cultivars were also examined.
RESULTS: Frequencies of CBD-type, intermediate-type, and THC-type feral plants were 0.88, 
0.11, and 0.01, respectively. Although total cannabinoid content varied substantially, the 
three groupings were perfectly correlated with CBDAS genotypes. Genotype frequencies 
observed in the test cross were consistent with codominant Mendelian inheritance of the 
THC:CBD ratio. Despite significant mean differences in total cannabinoid content, CBDAS 
genotypes blindly predicted the THC:CBD ratio among clinical cultivars, and the same was 
true for industrial grain cultivars when plants exhibited >0.5% total cannabinoid content.
CONCLUSIONS: Our results extend the generality of the inheritance model for THC:CBD 
to diverse C. sativa accessions and demonstrate that CBDAS genotyping can predict the 
ratio in a variety of practical applications. Cannabinoid profiles and associated CBDAS 
segregation patterns suggest that feral C. sativa populations are potentially valuable 
experimental systems and sources of germplasm.
  KEY WORDS   Cannabaceae; CBDA synthase; chemotype; genetic markers; hemp; 
marijuana.
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Synthesis of CBD and THC involves a common precursor, can-
nabigerolic acid or CBGA (Taura et al., 1995) (Fellermeier et al., 
2001), and the inheritance of major chemotypes is consistent with 
single-locus Mendelian codominance (de Meijer et al., 2003). de 
Meijer et al. (2003) proposed a model in which alternate alleles de-
termine THC-type and CBD-type in the respective homozygous 
plants, whereas heterozygous plants have the intermediate-type. 
However, DNA sequencing uncovered the presence of separate but 
tightly linked loci for the THCA synthase (THCAS) and CBDA syn-
thase genes (CBDAS), respectively (van Bakel et al., 2011; Onofri 
et al., 2015; Weiblen et al., 2015; Grassa et al., 2018 [Preprint]; 
Laverty et al., 2019). Given the impact of the THC:CBD ratio on 
various licit and illicit uses, developing molecular markers to more 
completely diagnose its genetic basis can aid efforts to regulate and 
improve C. sativa.
Predicting the THC:CBD ratio from a PCR-based assay was 
first claimed by Pacifico et al. (2006), but primers were not made 
available. Rotherham and Harbison (2011) reported a set of 
single nucleotide polymorphism (SNP) markers based on dif-
ferences between “drug-type” and “fiber-type” THCAS (Kojoma 
et al., 2006), but the latter THCAS sequence was reclassified by 
Laverty et al. (2019) as cannabichromenic acid synthase (CBCAS). 
These SNP markers and others derived from THCAS sequence 
(Staginnus et al., 2014) can distinguish THC-type and CBD-type 
plants, but they fail to differentiate THC-type from intermedi-
ate-type plants (Toth et al., 2020).
In an F2 mapping population derived from a cross of THC-
type and CBD-type, we reported the correspondence of three 
THC:CBD ratio classes with different combinations of CBDAS 
alleles, noting a four-base, frame shift deletion near the 5′ end of 
the CBDAS sequence in THC-type plants (Weiblen et al., 2015). 
From this observation, we hypothesized a model of chemotype 
inheritance in which plants that are homozygous for nonfunc-
tional and functional CBDAS have THC-type and CBD-type can-
nabinoid ratios. Plants that are heterozygous at the CBDAS locus 
have the intermediate type. The opportunity to test the validity 
of the model and its utility for predictive genotyping has only 
recently emerged with greater access to diverse populations of C. 
sativa (Toth et al., 2020).
We applied a research protocol approved by the U. S. Drug 
Enforcement Administration (DEA) to study feral C. sativa in 
the Minnesota River Valley (Fig. 2), aiming to test the CBDAS 
inheritance model that emerged from our previous mapping 
study. We confirmed that cannabinoid profiles and CBDAS gen-
otypes of feral individuals are congruent with the model, as 
was the segregation of genotypes and phenotypes in a feral test 
cross. Additionally, we tested samples obtained blindly from the 
National Institute on Drug Abuse (NIDA) to validate the model 
by predicting the cannabinoid ratios of 20 clinical cultivars. 
Lastly, we demonstrated the utility of the CBDAS assay for pre-
dicting THC:CBD ratios in regulated crops by genotyping 12 
Canadian-certified grain cultivars.
FIGURE 1. Cannabinoid biosynthesis occurs in glandular trichomes borne primarily on pistillate inflorescences composed of leaves, bracts, and flo-
rets. (A) Pistillate inflorescence with receptive, white stigmas before pollination. Scale bar = 1 cm. Photo credit: George Weiblen. (B) Scanning electron 
micrograph of an immature pistillate floret enclosed by a pair of imbricate bracts (br1 and br2) bearing multicellular hairs. Scale bar = 0.1 mm. Photo 
credit: David Marks. (C) Scanning electron micrograph of stalked glandular trichomes (gt), sessile glands (sg), and cystoliths (cy). Cystoliths are pointed 
hairs containing calcium carbonate crystals. Scale bar = 100 µm. Photo credit: David Marks. (D) Biosynthesis of major cannabinoid compounds. CBDA 
and THCA are produced enzymatically from a common CBGA precursor by different enzymes. Both compounds may be decarboxylated to pharmaco-
logically active neutral forms CBD and THC, respectively.
A DB
C
 October 2020, Volume 107 • Wenger et al.—CBDA synthase genotype predicts THC:CBD ratio in C. sativa • 1425
MATERIALS AND METHODS
Feral C. sativa
Minnesota feral plants were sampled in two successive years from 
sites located along the riparian corridor near the confluence of the 
Minnesota and Mississippi rivers (Fig. 2C). In 2015, we harvested all 
aboveground biomass of 10 mature pistillate plants from each of two 
locations. In 2016, we collected from the same two sites and a third 
location by harvesting only the terminal 15 cm of the apical infructe-
scence of 100 mature pistillate plants each. At one of the resampled 
locations, three clandestinely planted individuals were encountered 
but excluded from statistical analysis because they did not represent 
the feral population. The total feral sample size was N = 317. Field 
harvested plants and samples were dried in the laboratory for 3 weeks 
at ambient conditions and separated into seed and floral fractions.
NIDA clinical C. sativa
Dried, unpollinated pistillate inflorescences representing 20 culti-
vars were obtained from the University of Mississippi production 
facility with authorization from NIDA. Cannabinoid profiles of the 
NIDA cultivars were not shared with the University of Minnesota 
until after genotyping had been completed.
Canadian industrial C. sativa
Twelve industrial cultivars were grown from Canadian-certified 
planting seed during June through September 2017 at the Minnesota 
Agricultural Experiment Station (MAES) in Saint Paul, Minnesota. 
Five mature, pistillate (or monecious) plants were sampled at 70 
days after planting from each cultivar, and four additional samples 
of each variety were collected at 105 days. Sampling of tissue at 
MAES was conducted in the same manner as described above for 
feral plants, yielding an industrial C. sativa sample of N = 108 with 
nine samples per cultivar.
Cannabinoid profiling
Dried floral tissue samples were analyzed using gas chromatogra-
phy (ElSohly et al., 2000) to measure the percentage of total inflo-
rescence dry mass of seven compounds: cannabichromene (CBC), 
CBD, cannabigerol (CBG), cannabinol (CBN), delta-8-tetrahydro-
cannabinol (d8-THC), THC, and tetrahydrocannabivarin (THCV). 
We report percentage cannabinoid content as the sum of the in-
dividual compounds. Cannabinoid profiling was conducted on all 
field-collected feral plants, a pistillate plant grown from feral seed in 
the laboratory, six test-cross offspring of the feral parent, 20 NIDA 
clinical cultivars, and 108 field-grown plants of industrial C. sativa.
CBDAS sequencing
We tested the inheritance model for the THC:CBD ratio by 
genotyping functional (CF) and nonfunctional alleles (CX) of 
CBDAS (Fig. 3A). Homozygous plants with CXCX and CFCF gen-
otypes were predicted to have THC-type and CBD-type canna-
binoid ratios, respectively, whereas heterozygous plants (CFCX) 
were predicted to have an intermediate ratio. CBDAS genotypes 
of 20 field-collected feral plants, two lab-reared feral offspring, 
and six test-cross-derived plants were determined by Sanger 
sequencing of ~960 bp following the method previously re-
ported in our mapping study (Weiblen et al., 2015). PCR prod-
ucts were amplified with CBDAsynFor (ATG AAG TGC TCA 
ACA TTC) and CBDA961Rev (CCA CTC CAC CAA GGA 
AAA C) from gDNA isolated using a Plant DNeasy Kit (Qiagen, 
Hilden, Germany). Briefly, products were sequenced from the 
CBDAsynFor primer and aligned for comparison to reference 
CBDAS sequence (GenBank accession KJ469374) using Geneious 
10.2.5 (Biomatters, Ltd., Auckland, New Zealand).
CBDAS gel assay
Genotypes of 297 feral plants, 20 NIDA clinical cultivars, and 
108 industrial C. sativa plants were determined using a cleaved 
FIGURE 2. Distribution of feral Cannabis sativa in Minnesota, United States and study sample locations. (A) Location of Minnesota in North America. 
(B) Localities of Minnesota Department of Natural Resources observations and University of Minnesota herbarium (MIN) records from the Bell Museum. 
(C) Three feral population localities sampled near the confluence of the Minnesota and Mississippi rivers. Precise locations are non-public data avail-
able upon request.
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amplified polymorphic sequence (CAPS) assay (Fig. 3B) that ex-
ploits a Bst1107I recognition site (GTATAC) present in functional 
(CF) but absent in nonfunctional (CX) alleles of CBDAS. PCR prod-
ucts for the CAPS assay were obtained as described above. DNA 
was isolated from floral tissue using a modified cetyl trimethylam-
monium bromide (CTAB) extraction buffer and organic extraction 
(Doyle and Doyle, 1987), precipitated using sodium acetate and 
ethanol, and digested with FastDigest Bst1107I (Thermo Fisher 
Scientific, Waltham, MA, USA). Digested fragments were sepa-
rated on 0.8% agarose/1X TAE gels. Genotypes were scored by 
comparing digested fragment lengths of CBDAS PCR products to 
sequence-verified control samples (Fig. 3B). CBDAS CAPS geno-
typing of 56 test cross offspring was also performed on DNA iso-
lated from hulled seeds using the REDExtract-N-Amp Seed PCR 
Kit (Millipore Sigma, Burlington, MA, USA).
Feral offspring test cross
Using previously reported germination and growth protocols 
(Weiblen et al., 2015), we reared offspring of a single feral inter-
mediate-type plant known to be heterozygous (CFCX) for CBDAS 
(Fig. 3C). Among the offspring, we crossed a heterozygous pis-
tillate plant (CFCX) with a staminate plant that was homozygous 
for nonfunctional CBDAS (CXCX). We collected mature seed 
from the cross to compare the frequency of expected and ob-
served allelic combinations in the F2 generation using a G-test 
for goodness-of-fit.
Statistical analyses
Multiple comparison tests (Tukey HSD) of mean cannabinoid 
content among feral, clinical, and industrial C. sativa plants, 
and among CBDAS genotypes by THC:CBD ratio classes were 
performed with the Least Squares function in JMP Pro 14.2.0 
software (SAS, Cary, NC, USA). A likelihood ratio test for good-
ness-of-fit was calculated with the Distribution function in JMP 
to detect departures from codominant Mendelian inheritance. A 
likelihood ratio test for departure from Hardy–Weinberg equi-
librium of observed feral CBDAS genotype frequencies was per-
formed with ExactoHW 1.1 software (Engels, 2009). Cannabinoid 
phenotypic data and CBDAS genotypes for individual plants are 
provided in Appendix S1.
RESULTS
Feral cannabinoids
Among 317 pistillate, feral plants, we observed three distinct 
THC:CBD ratio classes as measured by gas chromatography (Table 1; 
Fig. 4A). Plants with a CBD-type ratio (THC:CBD ≤ 0.1) were 
in greatest abundance at 88%, followed by intermediate-type 
FIGURE 3. Model of major chemotype inheritance corresponding to 
CBDAS genotype. (A) Monohybrid inheritance in which mating between 
heterozygous individual yields descendants that are homozygous for 
functional CBDAS (CFCF), homozygous for nonfunctional CBDAS (CXCX), 
or heterozygous (CFCX). The three classes have predominantly CBD, pre-
dominantly THC, or intermediate chemotypes. (B) Agarose gel CAPS 
genotyping assay derived from presence or absence of a Bst1107I recog-
nition site in functional (CF) and nonfunctional (CX) CBDAS alleles. In the 
first lane is Invitrogen 1 Kb Plus DNA Ladder (Thermo Fisher Scientific, 
Waltham, MA, USA). Lanes 2–4 are are verified genotypes from Weiblen 
et al. (2015), and lanes 5–7 are feral individuals representing each of the 
three genotypes. (C) Experimental verification of CBDAS inheritance by 
crossing a CFCX female with a CXCX male sibling offspring from a CFCX feral 
parent. Pedigree of (I) feral parents, (II) first generation offspring, and (III) 
predicted second generation offspring. The genotype of the feral pollen 
donor is uncertain (C?CX) but must have carried at least one non-func-
tional allele (CX).
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(THC:CBD ~1.0) at 11% and THC-type (THC:CBD ≥ 10.0) at 1%. 
Numbers of intermediate and THC-type plants at each of three 
sampling locations were 12, 20, 1, and 3, 1, 0, respectively. Total can-
nabinoid content per plant ranged from <1% to >10% and averaged 
2.80% ± 0.09 SE (Fig. 4C). The distribution was skewed in favor 
of most plants (62%) having less than 3% total cannabinoid content.
Feral CBDAS
CBDAS genotypes of feral plants (Table 1) matched the predictions 
of the model (Fig. 3A). All 280 CBD-type plants were homozy-
gous for functional CBDAS (CFCF), all 33 intermediate-type plants 
were heterozygous (CFCX), and all four THC-type plants were ho-
mozygous for nonfunctional CBDAS (CXCX). Allele frequencies 
among feral plants for functional and nonfunctional variants were 
CF = 0.94 and CX = 0.06, respectively. The observed frequency of the 
CXCX genotype (four plants) slightly exceeded the Hardy–Weinberg 
expectation (exact test, P = 0.0318).
Feral test cross
The test cross between a heterozygous, pistillate plant (CFCX) 
and a staminate plant homozygous for nonfunctional CBDAS 
(CXCX) was consistent with the inheritance of CBDAS genotypes 
TABLE 1. Cannabinoid ratio groups, CBDAS genotypes, and cannabinoid content of Minnesota feral, NIDA clinical, and Canadian certified industrial C. sativa. 
Cannabinoid content, including total cannabinoid content (TCC) is reported as the mean percentage of inflorescence dry mass ± SE.
N f Genotype %THC (SE) %CBD (SE) %TCC (SE)
Minnesota feral
CBD-type 280 0.88 CFCF 0.11 (0.00) 2.40 (0.08) 2.71 (0.09)
Intermediate 33 0.11 CFCX 1.42 (0.11) 1.85 (0.15) 3.57 (0.28)
THC-type 4 0.01 CXCX 2.62 (0.48) 0.21 (0.06) 3.08 (0.53)
NIDA clinical
CBD-type 6 NA CFCF 0.19 (0.01) 4.94 (0.27) 5.39 (0.30)
Intermediate 11 NA CFCX 3.25 (0.28) 4.12 (0.26) 7.91 (0.55)
THC-type 3 NA CXCX 13.31 (0.27) 0.04 (0.00) 14.12 (0.29)
Industrial hemp
CBD-type 101 0.94 CFCF 0.07 (0.00) 1.45 (0.09) 1.62 (0.10)
Intermediate 7 0.06 CFCX 0.64 (0.07) 0.96 (0.11) 1.71 (0.19)
FIGURE 4. Cannabinoid profiles of Minnesota feral and industrial C. sativa sampled across 12 field-grown Canadian certified grain and dual use cultivars. 
(A) Percentage dry mass THC versus CBD among 317 Minnesota feral plants. The horizontal dashed line marks the 0.3% THC statutory threshold, and 
the solid line indicates a 1:1 THC:CBD ratio. Symbols for CBDAS genotypes are + (CXCX), ▲ (CFCX), and ● (CFCF). (B) Percentage dry mass THC versus CBD 
among 108 industrial hemp plants representing 12 Canadian-certified grain cultivars (9 samples/variety) grown in Saint Paul, Minnesota. (C) Distribution 
of total cannabinoid content among 317 Minnesota feral plants. (D) Distribution of total cannabinoid content among the 108 industrial hemp plants.
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according to a single-locus Mendelian factor. Genotyping of 62 
offspring of the test cross yielded nearly equal proportions of 
the two predicted genotypes and a few individuals of an unex-
pected third genotype (29 CXCX, 30 CFCX, and 3 CFCF). Genotype 
frequencies were not significantly different from expectations 
(G = 0.017; P = 0.90; Fig. 3C). The three offspring homozygous 
for functional CBDAS could have resulted from self-pollination 
given the occurrence of occasional, adventitious staminate flow-
ers in pistillate inflorescences. Male sex expression is commonly 
observed at low frequency in genetically female C. sativa plants 
(Hirata, 1927).
NIDA C. sativa
Blind genetic testing of 20 NIDA clinical cultivars yielded all three 
CBDAS genotypes (Table 1). Total cannabinoid content in the clin-
ical samples ranged from 4.5% to 14.7% (mean = 8.1% ± 0.7 SE) 
and was significantly greater on average than Minnesota feral C. 
sativa (Tukey HSD: t = −15.08, df = 442; p < 0.0001). Regardless of 
total cannabinoid content, the THC:CBD ratios revealed after geno-
typing perfectly matched model predictions based on the observed 
CBDAS genotypes (Table 1).
Industrial C. sativa
Among 108 field-grown plants representing 12 Canadian-
certified grain cultivars (including four dual use, grain/fiber 
cultivars), 101 individuals were homozygous for functional 
CBDAS (CFCF), and seven were heterozygous (CFCX). Each of 
the seven heterozygotes had an intermediate THC:CBD ra-
tio and exceeded the <0.3% THC statutory threshold (Table 
1; Fig. 4B). A subset of the homozygous plants (20 of 101) had 
intermediate THC:CBD ratios but had significantly lower to-
tal cannabinoid content (mean = 0.40% ± 0.04 SE) than either 
heterozygous intermediates (mean = 1.71% ± 0.19 SE; Tukey 
HSD: t = 3.62, df = 105, P = 0.0013) or homozygous CBD-type 
plants (mean = 1.93% ± 0.10 SE; Tukey HSD: t = 7.42, df = 105, 
P < 0.0001). Compared to feral C. sativa, Canadian-certified 
cultivars collectively had significantly lower cannabinoid con-
tent (mean = 1.63% ± 0.10 SE; Tukey HSD: t = 6.93, df = 442, 
P < 0.0001) and a similarly skewed distribution but with a far 
greater proportion of plants (90%) containing less than 3.0% to-
tal cannabinoid content (Fig. 4D).
DISCUSSION
Cannabinoids
It is not widely known that the discovery of CBD can be traced 
to Minnesota where it was first isolated from fiber-type C. sativa 
(Adams et al., 1940). Loss of access to Philippine fiber during 
World War II prompted the Defense Plant Corporation, a U. S. 
federal agency, to temporarily license and subsidize C. sativa cul-
tivation in Minnesota (Dewey, 1943). Escape and naturalization 
resulted in widespread populations of feral C. sativa throughout 
the upper Midwest (Nugent, 1938; Schoenrock, 1966). We used 
Minnesota feral C. sativa to validate a predictive model for the 
inheritance of the THC:CBD ratio. Genotyping of clinical and in-
dustrial C. sativa suggests a general association between allelic 
variation at the CBDAS locus and the three main classes of the 
THC:CBD ratio.
CBDAS in feral C. sativa
The complete correspondence of THC:CBD ratio classes with 
CBDAS genotypes in Minnesota feral C. sativa provides strong ev-
idence for the generality of the model of inheritance that was de-
rived from inbred biparental genetic mapping (Fig. 3A) (Weiblen 
et al., 2015). Also supporting generality were sequences from 20 
feral, THC-type or intermediate plants sharing the same diagnostic 
four-base frameshift deletion previously reported for nonfunctional 
CBDAS isolated from THC-type C. sativa (Weiblen et al., 2015). 
Using the CAPS assay based on this diagnostic deletion, an addi-
tional 297 feral plants also associated CBDAS genotypes with the 
three THC:CBD ratio groups. The marginally significant departure 
of CBDAS genotype frequencies from Hardy–Weinberg equilib-
rium might represent a Type I statistical error given only four THC-
type plants among 317 individuals. Additional study is needed to 
evaluate the potential for non-equilibrium processes to have shaped 
feral CBDAS genotype frequencies, including the possibility of phe-
notypic selection for cannabinoids as deterrents to seed predation 
(Small, 2016).
Identifying THC-type plants among first generation offspring of 
a feral intermediate plant signaled the presence of pollen donors 
harboring THC-type alleles as would be expected in a segregating 
field population. Experimental crossing of offspring from a feral in-
termediate produced 59 of 62 genotypes that were consistent with 
the expected segregation of CBDAS genotypes in the subsequent 
generation.
Unexplained cannabinoid variation
Despite evidence from feral C. sativa for incomplete dominance af-
fecting the THC:CBD ratio, variance within each of the three ratio 
classes remains unexplained and deserves further study. Similar to 
the segregating population of Weiblen et al. (2015), variation was 
greatest among the feral intermediate class (Fig. 4A), and interme-
diate-type plants had slightly higher quantities of CBD than THC. 
Considering that these two cannabinoids share a common precur-
sor (CBG), we speculate that CBDAS is a superior competitor to 
THCAS either in terms of substrate affinity or catalytic efficiency. 
Industrial C. sativa had the same pattern (Fig. 4B), although with 
less variation within classes than feral C. sativa, as would be ex-
pected for a domestic crop variety.
Another major component of cannabinoid variation not ex-
plained by the THC:CBD ratio model is the nearly 10-fold range 
in total cannabinoid content (Fig. 4C, D). A broad range of varia-
tion was observed in all three ratio classes (Fig. 4A, B), indicating 
that the inheritance of cannabinoid quantity is independent of the 
THC:CBD ratio. Quantitative trait locus (QTL) analysis identified 
QTL for total cannabinoid content on five different chromosomes 
(Grassa et al., 2018 [Preprint]), and none were linked to the sin-
gle QTL that is strongly associated with the THC:CBD ratio or the 
genes for CBDAS and THCAS on chromosome 7 (Fig. 5A). Whether 
any of the independent QTLs are associated with differential gene 
regulation affecting CBD or THC production is an intriguing ques-
tion for future study. Alternatively, it has been hypothesized that 
cannabinoid gene copy number influences potency (Kovalchuk 
et al., 2020).
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Assaying clinical and industrial C. sativa
We extended the utility of the CBDAS assay by blindly geno-
typing 20 clinical cultivars obtained from the NIDA production 
facility in Mississippi. Only after genotyping were the cannabi-
noid profiles from Mississippi shared with the investigators in 
Minnesota. CBDAS genotypes predicted the three THC:CBD ra-
tio classes with 100% accuracy, suggesting that CBDAS genotypes 
can generally predict THC:CBD ratios in drug cultivars. Applying 
the assay to a set of 108 samples from 12 Canadian-certified in-
dustrial cultivars (grain and dual-use) also suggest broad diag-
nostic utility.
We were surprised to discover that 6% of plants grown from 
Canadian-certified seed exceeded the <0.3% THC statutory defi-
nition of industrial C. sativa. All seven plants had an intermediate 
THC:CBD ratio and the expected heterozygous CBDAS genotype. 
Had THC testing been performed on homogenized samples taken 
from multiple plants or if the results of several independent tests 
were averaged for a given population, the low frequency of non-
compliant plants could have escaped detection during the multipli-
cation of certified seed. Even the most stringent THC testing when 
developing foundation seed or multiply-
ing certified seed could be confounded 
by pollen drift from nearby feral or cul-
tivated C. sativa harboring THC-type 
alleles (Small and Antle, 2003). Stokes 
et al. (2000) reported up to 36% C. sativa 
pollen during August in airborne pollen 
samples from the midwestern United 
States. Aerodynamic models of pollen 
dispersal could be tested in the field to 
evaluate whether the recommended 
isolation distance of 5 km is sufficient 
to maintain the genetic purity of a C. sa-
tiva crop. Regardless, the contractual ob-
ligation to neither plant nor multiply seed 
saved from a certified crop is especially 
important given the potential for pollen 
contamination to increase the frequency 
of plants with >0.3% THC in subsequent 
generations.
There are several situations in which 
the CBDAS genotype assay might have 
practical value. Many populations of C. 
sativa classified as "hemp" are segregating 
for THC-type alleles (Toth et al., 2020). 
The risk of THC-type alleles contami-
nating certified fiber and grain cultivars 
could be minimized by screening seed 
lots at all stages of breeding and mul-
tiplication to assure purity. When seed 
provenance is uncertain or questionable, 
genetic testing of samples prior to plant-
ing could reduce the risk of non-com-
pliant crops. Farming “industrial hemp” 
is a risky proposition at present because 
crops are tested near maturity for THC 
regulatory compliance.
The homozygous functional CBDAS 
genotype accurately identified all 101 
industrial C. sativa plants that were compliant with the <0.3% 
THC statutory definition of industrial hemp. However, 20 plants 
among the compliant individuals had exceptionally low total can-
nabinoid content (<0.5%). When cannabinoids were this scarce, the 
THC:CBD ratio was closer to intermediate type than to either the 
THC-type or CBD-type. Uncertainty associated with sample prepa-
ration or gas chromatography in the range of ±0.1–0.3% might have 
skewed the THC:CBD ratio and obscured the distinction between 
the intermediate and CBD-type. Alternatively, novel genetic mech-
anisms might await discovery. In any event, the homozygous func-
tional CBDAS genotype correctly predicted that even these 20 
plants were compliant with the <0.3% THC statutory definition of 
industrial C. sativa.
THC:CBD ratio inheritance model
The CBDAS genotype accurately predicted all three THC:CBD 
ratio classes in diverse C. sativa gene pools, supporting its broad 
utility. The simplest genetic explanation for this association would 
be if CBDAS and THCAS represent alternate alleles of a single lo-
cus (de Meijer et al., 2003). However, there are at least two or more 
FIGURE 5. (A) Alignment of a chromosome 7 physical map for C. sativa (Grassa et al., 2018) with the 
corresponding linkage group from the segregating F2 population of Weiblen et al. (2015). A single 
QTL at 38.9 cM, accounting for >90% of variance in the THC:CBD ratio, maps to a region between 20.6 
Mb and 31.5 Mb on chromosome 7. Genes for THCAS and CBDAS are located within this region at 26 
Mb and 31 Mb, respectively. (B) Model in which THC-type and CBD-type plants are reciprocally homo-
zygous for alternately functional (f ) and nonfunctional (x) alleles of THCAS and CBDAS. Intermediate-
type plants are heterozygous at both loci. (C) Punnett square for selfing the F1 intermediate of a 
hybrid cross. According to the close linkage of the loci, we predict that recombinants are not likely to 
be observed among the F2 descendants of hybrid crosses.
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tightly linked cannabinoid synthase loci in diverse accessions of 
C. sativa (van Bakel et al., 2011; Onofri et al., 2015; Weiblen et al., 
2015; Grassa et al., 2018 [Preprint]; Laverty et al., 2019). Recent 
annotation of several C. sativa genome assemblies (Grassa et al., 
2018 [Preprint]; Laverty et al., 2019), including one anchored with 
whole-genome shotgun sequencing of an F2 mapping population 
(Weiblen et al., 2015), indicate that separate loci for THCAS and 
CBDAS are tightly linked in a chromosomal region of highly sup-
pressed recombination. Grassa et al. (2018; Preprint) proposed the 
physical arrangement of the synthases in close proximity on chro-
mosome 7 (Fig. 5A). Based on these findings, we suggest a mech-
anistic model explaining the predictive power of the CBDAS 
genotype with respect to THC:CBD inheritance. In CBD-type 
plants, the expressed CBDAS is tightly linked to a nonfunctional 
and/or under-expressed THCAS. In THC-type plants, a nonfunc-
tional and underexpressed CBDAS is tightly linked to a functional 
and overexpressed THCAS. Tight genetic linkage of the synthases 
renders CBD-type and THC-type plants reciprocally homozygous 
for the respective alleles, whereas intermediate plants are recipro-
cally heterozygous (Fig. 5C).
The conserved four-base deletion at position 153 in the CBDAS 
sequence that renders it nonfunctional (Weiblen et al., 2015) and 
is the target of the CAPS assay appears to exist in THC-type and 
intermediate plants among diverse C. sativa accessions (Table 2). 
Although the model of incomplete dominance for the THC:CBD 
ratio seems robust, it does not completely account for cannabi-
noid inheritance. In particular, the potential influence of gene copy 
number on cannabinoid expression deserves further consideration 
(Kovalchuk et al., 2020).
CBDAS versus THCAS
When the first CBDAS sequence was published Taura et al. (2007) 
reported additional homologs in fiber-type C. sativa. Subsequent 
studies have suggested that cannabinoid synthase and synthase-like 
sequences are likely duplicated (Onofri et al., 2015; Weiblen et al., 
2015). BLAST searches with the original CBDAS sequence return 
no fewer than 37 hits described as CBDAS compared to 94 hits 
described as THCAS with the first reported THCAS sequence 
(Sirikantaramas et al., 2004). The CBDA961Rev primer reported 
here amplifies CBDAS (CF) and nonfunctional CBDAS (CX) to the 
exclusion of potentially confounding cannabinoid synthase gene 
copies (Table 2). The association of functional and nonfunctional 
CBDAS alleles with THC-type plants and intermediate plants has 
also been independently affirmed in a broader survey of European 
C. sativa (Cascini, 2019) and in feral New York populations (Toth 
et al., 2020). Functional CBDAS is present in the genome of the 
CBD-type cultivar Finola but absent from the THC-type Purple 
Kush (Laverty et al., 2019). As predicted by the model, a CBDAS 
sequence bearing the four-base (CX) deletion is found in the Purple 
Kush genome assembly but not in Finola.
We suggest that CBDAS genotype assays may be more infor-
mative than existing THCAS polymorphisms because the latter 
alone do not yet distinguish THC-type plants from intermediates 
(Rotherham and Harbison, 2011; Staginnus et al., 2014). One ex-
planation for the limited diagnostic power of THCAS-based assays 
is that a conserved and presumably nonfunctional allele of THCAS 
has not been identified. Cannabinoid synthase sequences from both 
drug and fiber cultivars previously thought to be copies of THCAS 
TABLE 2. Cannabinoid synthase sequence alignment including the four-base deletion that distinguishes functional (CF) from nonfunctional (CX) alleles of cannabidiolic 
acid synthase (CBDAS). A Bst1107I restriction site spans the deletion. Downstream sequences from 943 to 961 bp illustrate how the reverse primer CBDA961Rev 
selectively amplifies CBDAS over other cannabinoid synthases. Gene sequences are annotated as CBDAS, CBDAS-like, THCAS, or CBCAS according to Grassa et al. (2018) 
for cultivars including Carmen hemp (Weiblen et al., 2015), CBDRx (Grassa et al., 2018), drug type (Sirikantaramas et al., 2004), fiber type (Taura et al., 2007), Finola 
(Laverty et al., 2019), Purple Kush (Laverty et al., 2019), and Skunk #1 (Weiblen et al., 2015).
Sequence position (bp)
Gene Cultivar Accession Bst1107I CBDA961 reverse complement  
142                  153 170...943 961
CBDAS (C F) Carmen KJ469374 AATCTAAAACTCGTATACACTCAAAACAA…….GTTTTCCTTGGTGGAGTGG
CBDAS (C F) fiber type AB292682 AATCTAAAACTCGTATACACTCAAAACAA…….GTTTTCCTTGGTGGAGTGG
CBDAS (C F) Finola CM011610 AATCTAAAACTCGTATACACTCAAAACAA…….GTTTTCCTTGGTGGAGTGG
CBDAS (C F) CBDRx LR213635 AATCTAAAACTCGTATACACTCAAAACAA…….GTTTTCCTTGGTGGAGTGG
CBDAS (C X ) Skunk #1 KJ469375 AATCTAAAACT----TACACCCAAAACAA…….GTTTTCCTTGGTGGAGTGG
CBDAS (C X ) Skunk #1 KJ469376 AATCTAAAACT----TACACCCAAAACAA…….GTTTTCCTTGGTGGAGTGG
CBDAS (C X ) Purple Kush CM010792 AATCTAAAACT----TACACCCAAAACAA…….GTTTTCCTTGGTGGAGTGG




THCAS Skunk#1 KJ469378 AATCCAAAACTCGTATACACTCAACACGA……ATTTTTCATGGTGGAGTGG
THCAS drug type AB057805 AATCCAAAACTCGTATACACTCAACACGA……ATTTTTCATGGTGGAGTGG
CBCAS Purple Kush JH227480 AATCCAAAATTCATATACACTCAACACGA……ATTTTTCTTGGTGGAGTGG
CBCAS Carmen KJ469380 AATCCAAAATTCATATACACTCAACACGA……ATTTTTCTTGGTGGAGTGG
CBCAS Skunk #1 KJ469379 AATCCAAAATTCATATACACTCAACACGA……ATTTTTCTTGGTGGAGTGG
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(Kojoma et al., 2006; Weiblen et al., 2015) turned out to be cannabi-
chromenic acid synthase (CBCAS) according to Laverty et al. (2019). 
Adding to the confusion, sequences from CBD-type plants anno-
tated by Rotherham and Harbison (2011) as THCAS are more sim-
ilar to CBCAS (Grassa et al., 2018 [Preprint]; Laverty et al., 2019). 
It is possible that the high sequence similarity of different synthase 
genes and subsequent misidentification have confounded efforts to 
develop diagnostic assays of the THC:CBD ratio based on THCAS 
polymorphisms. Perhaps it is the highly suppressed recombination 
in the physical region harboring reciprocally linked, functional and 
nonfunctional alleles that maintains the single locus-like pattern of 
cosegregation. This hypothesis predicts the existence of a nonfunc-
tional THCAS allele that might yield a THCAS-based codominant 
assay similar to the CBDAS-based assay (Fig. 5C).
Feral problems and prospects
Due to research restrictions resulting from the Controlled 
Substances Act of 1970, few data on the cannabinoid profiles or 
genetics of feral C. sativa were available until recently (Datwyler 
and Weiblen, 2006). The rarity of THC-type plants in feral popu-
lations and the odds of locating one-in-a-hundred are consistent 
with the popular opinion that “ditch weed” is non-intoxicating. 
Our findings are at the same time consistent with law enforce-
ment concerns about feral populations concealing drug-type C. 
sativa, although their low frequency undercuts the efficiency of 
drug eradication. We would like to know whether the presence of 
THC-type and intermediate-type plants in feral populations is due 
to the impurity of historical fiber cultivars or to more recent intro-
gression of THC-type genetics from clandestine drug operations.
Two arguments favor historical impurity. First, THC and CBD 
were not characterized chemically until long after the introduction 
of fiber hemp to Minnesota such that neither breeders nor produc-
ers of hemp could accurately assess purity. Second, THC-type pollen 
is unlikely to be abundant in the landscape relative to feral pollen 
based on horticultural practice for drug production. Unpollinated 
inflorescences are known to invest resources in excessive trichome 
formation and cannabinoid production (Merlin and Clark, 2013). 
Drug operations either cultivate clonally propagated pistillate plants 
(females) or remove staminate plants (males) to avoid pollination 
and increase the potency of the crop.
Alternatively, the nonfunctional CBDAS allele might have been 
introduced to feral populations by dispersal of THC-type pollen from 
cultivation and escape of drug-type C. sativa. Pollen can travel dis-
tances up to kilometers in wind-pollinated species such as C. sativa, 
and long-distance seed dispersal by birds has even greater potential 
to influence the migration of genes among populations (Small, 2016). 
Additional work is needed to examine population genetic patterns 
and processes by sampling feral C. sativa geographically and by com-
paring locations with different histories of fiber and drug cultivation.
Feral populations could be a valuable source of germplasm for 
breeding and provide opportunities to investigate the inheritance 
of quantitative variation in total cannabinoid content (potency). 
Genetic mechanisms influencing cannabinoid quantity are cur-
rently a subject of untested speculation. None of the QTL for po-
tency that have been identified are linked to THCAS or CBDAS but 
are rather associated with different chromosomes (Weiblen et al., 
2015; Grassa et al., 2018 [Preprint]). Breeding to increase the yield 
of CBD while maintaining THC levels below the legal limit is an 
obvious potential application, as is breeding for fiber and grain 
yield. At least 70 generations of feral adaptation to regional soil and 
climate conditions present both opportunities and challenges for 
re-domestication.
Broader implications
The presence of more than one of the three cannabinoid classes in 
feral, industrial, and clinical populations renders the dichotomy be-
tween “hemp” and “marijuana” meaningless from a botanical perspec-
tive. Other classes of plants add to the complexity of C. sativa. For 
example, Fournier (2004) reported cultivars producing mostly CBG, 
the common precursor to THC and CBD. We avoided using common 
names not simply because they misrepresent patterns in nature and 
fail to match statutory intent. The dichotomy between “hemp” and 
“marijuana” perpetuates culturally biased and pejorative assumptions 
about C. sativa that have hindered scientific investigation for nearly a 
century (Abel, 1980). Rooted in colonial history, North American C. 
sativa has literally and figuratively escaped from that past, adapting 
and thriving today across a diverse array of natural ecosystems and 
engineered systems. A decolonized definition recognizing THC-type, 
CBD-type, intermediate-type, and CBG-type plants would be more 
accurate botanically and perhaps more practical as the use and regu-
lation of C. sativa continues to expand and diversify.
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